Tags

Type your tag names separated by a space and hit enter

Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
Bone. 2008 Jun; 42(6):1235-9.BONE

Abstract

Fibroblast growth factor 23 (FGF23) plays important roles in the development of hypophosphatemic diseases such as tumor-induced osteomalacia (TIO) and X-linked hypophosphatemic rickets/osteomalacia (XLH). However, clinical usefulness of measurement of FGF23 has not been established. The objective of this study is to examine the importance of FGF23 measurement in the diagnosis of hypophosphatemic diseases. Biochemical parameters concerning phosphate metabolism were analyzed in a cross-sectional study. 32 patients with TIO, 28 patients with XLH and 16 hypophosphatemic patients with other causes including vitamin D deficiency, Fanconi's syndrome and Cushing's syndrome were studied. In patients with TIO and XLH, FGF23 was above the upper limit of the reference range in most patients irrespective of medical treatment. The lowest FGF23 in these patients was 38.0 pg/ml. FGF23 in hypophosphatemic patients with other causes was undetectable (less than 3 pg/ml) in 12 patients and the highest FGF23 in this group was 23.9 pg/ml. Relationship between phosphate and FGF23 indicated that TIO and XLH are diseases with high FGF23 and hypophosphatemia judged by age-dependent reference ranges for serum phosphate. FGF23 measurement is useful for differential diagnosis of hypophosphatemic diseases caused by excess actions of FGF23 and other etiologies. High FGF23 with low phosphate judged by age-dependent reference ranges for phosphate establishes the diagnosis of diseases caused by excess actions of FGF23.

Authors+Show Affiliations

Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medical Sciences, Tokushima 770-8503, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18396126

Citation

Endo, Itsuro, et al. "Clinical Usefulness of Measurement of Fibroblast Growth Factor 23 (FGF23) in Hypophosphatemic Patients: Proposal of Diagnostic Criteria Using FGF23 Measurement." Bone, vol. 42, no. 6, 2008, pp. 1235-9.
Endo I, Fukumoto S, Ozono K, et al. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone. 2008;42(6):1235-9.
Endo, I., Fukumoto, S., Ozono, K., Namba, N., Tanaka, H., Inoue, D., Minagawa, M., Sugimoto, T., Yamauchi, M., Michigami, T., & Matsumoto, T. (2008). Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone, 42(6), 1235-9. https://doi.org/10.1016/j.bone.2008.02.014
Endo I, et al. Clinical Usefulness of Measurement of Fibroblast Growth Factor 23 (FGF23) in Hypophosphatemic Patients: Proposal of Diagnostic Criteria Using FGF23 Measurement. Bone. 2008;42(6):1235-9. PubMed PMID: 18396126.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. AU - Endo,Itsuro, AU - Fukumoto,Seiji, AU - Ozono,Keiichi, AU - Namba,Noriyuki, AU - Tanaka,Hiroyuki, AU - Inoue,Daisuke, AU - Minagawa,Masanori, AU - Sugimoto,Toshitsugu, AU - Yamauchi,Mika, AU - Michigami,Toshimi, AU - Matsumoto,Toshio, Y1 - 2008/03/05/ PY - 2007/12/08/received PY - 2008/02/06/revised PY - 2008/02/13/accepted PY - 2008/4/9/pubmed PY - 2008/10/1/medline PY - 2008/4/9/entrez SP - 1235 EP - 9 JF - Bone JO - Bone VL - 42 IS - 6 N2 - Fibroblast growth factor 23 (FGF23) plays important roles in the development of hypophosphatemic diseases such as tumor-induced osteomalacia (TIO) and X-linked hypophosphatemic rickets/osteomalacia (XLH). However, clinical usefulness of measurement of FGF23 has not been established. The objective of this study is to examine the importance of FGF23 measurement in the diagnosis of hypophosphatemic diseases. Biochemical parameters concerning phosphate metabolism were analyzed in a cross-sectional study. 32 patients with TIO, 28 patients with XLH and 16 hypophosphatemic patients with other causes including vitamin D deficiency, Fanconi's syndrome and Cushing's syndrome were studied. In patients with TIO and XLH, FGF23 was above the upper limit of the reference range in most patients irrespective of medical treatment. The lowest FGF23 in these patients was 38.0 pg/ml. FGF23 in hypophosphatemic patients with other causes was undetectable (less than 3 pg/ml) in 12 patients and the highest FGF23 in this group was 23.9 pg/ml. Relationship between phosphate and FGF23 indicated that TIO and XLH are diseases with high FGF23 and hypophosphatemia judged by age-dependent reference ranges for serum phosphate. FGF23 measurement is useful for differential diagnosis of hypophosphatemic diseases caused by excess actions of FGF23 and other etiologies. High FGF23 with low phosphate judged by age-dependent reference ranges for phosphate establishes the diagnosis of diseases caused by excess actions of FGF23. SN - 8756-3282 UR - https://www.unboundmedicine.com/medline/citation/18396126/Clinical_usefulness_of_measurement_of_fibroblast_growth_factor_23__FGF23__in_hypophosphatemic_patients:_proposal_of_diagnostic_criteria_using_FGF23_measurement_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S8756-3282(08)00101-4 DB - PRIME DP - Unbound Medicine ER -